

Preliminary Research

Intravenous Magnesium for Complex Regional Pain Syndrome Type 1 (CRPS 1) Patients: A Pilot Study

Susan Collins, MSc,^{*†‡} Wouter W. A. Zuurmond, Prof, MD,^{*†} Jaap J. de Lange, Prof, MD,^{*} Bob J. van Hilten, Prof, MD,^{†§} and Roberto S. G. M. Perez, PhD^{*†‡}

^{*}Department of Anesthesiology, VU University Medical Center, Amsterdam; [†]Knowledge Consortium Trauma Related Neuronal Dysfunction, Leiden; [‡]The EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam; [§]Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands

ABSTRACT

Objectives. To explore the feasibility of intravenous magnesium administration as a potential candidate intervention for a large size trial in Complex Regional Pain Syndrome Type 1 (CRPS 1).

Design. Randomized clinical trial.

Setting. Outpatient pain clinic.

Patients. Ten CRPS 1 patients.

Interventions. Eight patients received 70 mg/kg magnesium sulphate infusions in 4 hours for 5 days. For blinding purposes, 2 patients received equal amount NaCl 0.9% solutions (data not analyzed or presented). Interventions were accompanied by standardized physical therapy.

Outcome Measures. Pain was assessed using an 11-point Box scale (three times daily for a week) and the McGill Pain Questionnaire. Skin sensitivity was measured with the Semmes Weinstein Monofilaments, (other) impairments with the Impairment Level Sumscore. In addition, functional limitations (Radboud Skills Questionnaire, questionnaire rising and sitting down) and quality of life (Short Form-36 [SF-36], EuroQol) were evaluated. Assessments were performed at baseline, 1, 3, 6, and 12 weeks after intervention.

Results. Mild systemic side effects were experienced and the infusions were locally well tolerated. Pain was significantly reduced at all follow up compared with baseline (T1: $P = 0.01$, T3: $P = 0.04$, T6: $P = 0.02$, T12: $P = 0.02$). McGill sensory subscale improved significantly at T1 (number of words chosen: $P = 0.03$ and pain rating index: $P = 0.03$). Impairment level ($P = 0.03$) and quality of life (EuroQol $P = 0.04$, SF-36 physical $P = 0.01$) were significantly improved at T12. No improvement was found for skin sensitivity and functional limitations.

Conclusion. Intravenous magnesium significantly improved pain, impairment and quality of life and was well tolerated. The results of this pilot study are encouraging and suggest that magnesium IV as a treatment in CRPS 1 should be further explored in a large size formal trial design.

Key Words. CRPS; NMDA Antagonists; Magnesium

Reprint requests to: Susan Collins, MSc, VU University Medical Center, Department of Anesthesiology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Tel: 0031-204440293; Fax: 0031-204444385; E-mail: s.collins@vumc.nl.

Introduction

Complex Regional Pain Syndrome type 1 (CRPS 1) is a painful disorder of the extremities that may occur after trauma. CRPS 1 is characterized by autonomic and motor dysfunction in combination with sensory complaints, such as

spontaneous pain, allodynia, and hyperalgesia [1–3].

Release of Reactive Oxygen Species, neuropeptides, and other mediators of inflammation (cytokines) [4] associated with an excessive (neurogenic) [5] inflammatory response [4,6,7], have been suggested to play a role in development or maintenance of CRPS [4,6,8,9]. This cascade involving (peripheral) trauma and inflammation may consequently induce sensitization of local structures (C and A δ -fibres), which elicit the release of glutamate. Continued release of glutamate activates α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) receptors by calcium release [10]. The calcium influx in turn depolarizes and releases the voltage dependent magnesium block and awakens the dormant N-methyl D-aspartate (NMDA) receptors. Activation of the NMDA receptors is key in the induction and continuation of peripheral and central sensitization [11–13], a process whereby structures involved in sensory processing are upregulated, resulting in an increased reaction to peripheral stimuli. This process of central sensitization and wind up [14] has been related to the occurrence of sensory complaints exhibited by CRPS 1 patients [15].

To counter this wind-up phenomenon and the vicious circle of sensitization, NMDA antagonists may be used [16]. Evidence in acute as well as chronic pain treatment suggests that magnesium [17–19], a physiologically competitive calcium antagonist, downregulates the activation of the NMDA receptors responsible for the generation of neuropathic pain [20]. Two recent placebo controlled randomized controlled trials, on magnesium IV in patients suffering from postherpetic neuralgia, and chronic pain patients of various etiology revealed a significant reduction of pain [20–22].

To our knowledge, the effects of magnesium on sensory disturbances in CRPS 1 patients has not been evaluated before. In the present pilot study, the feasibility with respect to efficacy, safety, and tolerability of a magnesium IV treatment on pain and other sensory complaints, functional status, and quality of life was evaluated in CRPS 1 patients.

Methods

Patients

CRPS 1 patients were recruited at the outpatient pain clinic of the VU University Medical Center. Patients had to meet the following inclusion criteria: 1) Diagnosis of CRPS 1 according to the

IASP criteria [23]; 2) A Visual Analog Scale (VAS) for spontaneous pain of 5 cm or higher in the previous week; 3) age between 18–70 years old; 4) CRPS 1 in one extremity; and 5) Patients had to give written informed consent. Patients were excluded in case of: 1) Another (2nd) chronic pain syndrome, interfering with pain ratings; 2) Other complaints interfering with functional tests; 3) Known kidney and/or severe liver disease; 4) Active infection; 5) Malignant disease; 6) Heart failure; 7) Pacemakers or implanted defibrillators; 8) Pulmonary congestion; and 9) Pregnancy.

Medication for the treatment of CRPS 1 (e.g., DMSO-crème and N-acetylcysteine), analgesics with NMDA antagonistic properties (ketamine, lidocaine, methadon, amandatine, dexomethorfan), and the use of (oral) magnesium had to be stopped for the duration of the trial, starting 1 week before the onset of the trial.

The study was approved by the Medical Ethical Committee of the VU University Medical center.

Intervention

In total, 10 patients were planned to be included in this study. Potential side effects of magnesium IV are mandatory reported in the patient information brochure. To limit the effect of bias due to expectancy and placebo effect as observed in open trials, two patients were allocated to placebo. Eight patients assigned to the magnesium group received 70 mg/kg magnesium sulphate continuously administered in 4 hours via an intravenous infusion (in two 50 mL syringe) of 25 mL/hour a day for a period of 5 days. The patients assigned to placebo received an equal amount of NaCl 0.9% solution (two 50 mL syringes) through a similar procedure. Treatment allocation was performed at random using a digital random number generator. Patients, researcher, and the physician were blinded for the type of intervention for the duration of the trial. As the placebo intervention was added for blinding purposes only, the data of these patients were not presented or analyzed in this study. Success of blinding was assessed at the end of the trial, by asking patients and researchers what intervention they thought the patients had received.

Concomitant use of analgesics (with the exception of strong opioids) was allowed and was given according to the guidelines established by the World Health Organization [24] and was registered daily in a pain diary. Regardless of the allocated intervention, all patients received standard physical therapy, given by a local therapist according to a fixed treatment protocol [8,25].

Measurements

Measurements were performed before the start of the intervention and at 1 (T1), 3 (T3), 6 (T6), and 12 (T12) weeks after the intervention. The assessments were carried out at the same time (e.g., morning or afternoon), under environmentally stable conditions, and were performed by a trained researcher according to a standardized protocol (with the exception of the questionnaires, which were filled out by the patients). The researcher attended regular training sessions three times per year in order to promote standardization of measurement.

Sensory Measurements

Patients had to record their pain on an 11-point Box scale three times daily for a period of one week in a pain diary before each measurement.

The McGill Pain Questionnaire [26] was recorded at each measurement point, and expressed in the number of words chosen (NWC) and the pain rating index (PRI) for the whole questionnaire (total) and the sensory, affective, and evaluative subscales.

The sensitivity of the skin was objectively measured with Semmes Weinstein Monofilaments (SWM) [27]. By comparing sensory scores of the affected extremity with the unaffected extremity, sensory thresholds differences can be determined. Monofilaments representing sensory cut-off points as established by the manufacturer were used, each representing a different force (ranging from 0.0045 to 447.0 g), whereby the procedure started with the smallest filament up to the largest. The testing areas for the (palmar side of the) hand, the distal phalanx of dig.1, the distal and proximal phalanx of dig.2, the distal and proximal phalanx of dig.5, and hypothenar of dig.5, were tested. The feet were tested on the plantar side: the distal phalanx dig.1, the distal phalanx dig.2, the distal phalanx dig.5, the arcus plantaris medialis, and the arcus plantaris lateralis.

Impairment Level Assessments

Patients' impairment level was assessed with the Impairment Level Sumscore (ISS) [28,29], in which pain (during movement) was measured by Box scale and the McGill Pain Questionnaire; temperature measured with infrared thermometer (First Temp Genius®, Sherwood Medical, Den Bosch, The Netherlands) [30]; volume measured with water weight volume measurements; and active range of motion (AROM) measurements were converted into a compound sumscore. The

ISS ranged from 5 to 50 whereby higher scores corresponded to higher levels of complaints.

Activity Level Assessments

The Radboud Skills Questionnaire (RSQ) [31] and the Walking questionnaire (WQ) and questionnaire rising and sitting down (QRSD) [32] were used to address the activity level of CRPS 1 patients for the upper and lower extremity, respectively.

Quality of Life Assessments

The Short Form-36 (SF-36) [33] and EuroQol [34] were used for the assessment of quality of life. The SF-36 was assessed at baseline and T12. In addition to the SF-36, the EuroQol was also assessed at T3.

Safety and Tolerability Measurements

Prior to the start of the intervention, creatinine levels and cardiac function (using 10 leads electrocardiograph [ECG]) were determined in each patient. Plasma levels of magnesium were recorded each infusion day prior to and after the intervention, in the (unaffected) arm.

ECG monitoring was performed continuously during the administration of the study medication up to 15 minutes after termination of the intervention.

Possible systemic and local side effects and adverse events were recorded during intervention by the researcher and registered by patient in the pain diary and evaluated according to European guidelines [35].

Statistical Analysis

The data were processed and analyzed using SPSS version 11. Median week pain scores were calculated for the Box scale per patient. Total and subscale pain scores for the McGill Pain Questionnaire were determined per patient. Mean SWM scores for either the hands or feet calculated per patient were used to determine median sensory differences between the affected and unaffected extremity. Sumscores were calculated for the ISS and its constituting items per patient. Furthermore, mean total scores were calculated for the RSQ, the WQ and QRSD, EuroQol and for the physical and mental domain of the SF-36 per patient.

Descriptive as well as comparative statistics were used, whereby the Wilcoxon test was used to compare follow-up data with baseline values in the magnesium group. Baseline group scores and changes at follow up compared with baseline were defined in medians and interquartile ranges.

Efficacy of Magnesium

Definition of efficacy of magnesium was determined a priori. Magnesium was considered to be sufficiently effective for further evaluation if: 1) At least 4 out of 8 patients receiving magnesium had a reduction of spontaneous pain of 50% or more as measured with the Box scale; 2) Or an improvement of two or more of the outcomes' sensitivity (measured with McGill Pain Questionnaire and SWM), impairment, activity, or quality of life were found.

Results

From April 2005 to 2007, 14 CRPS 1 patients were included from the outpatient clinic of the VU University Medical Center, from a total of 59 patients fulfilling the inclusion criteria (see Figure 1).

Reasons for not participating in the pilot study for the remaining 45 patients fulfilling the inclusion criteria were wishing conventional treatment with DMSO-crème and n-acetylcysteine (N = 7); fear of injections and infusions (N = 6); unwilling to receive placebo (N = 7); fear of side effects of magnesium (N = 2); intensity of intervention (N = 9); work related reasons (N = 7); unwilling to participate in research (N = 2); other (N = 5). No significant differences between participants and nonparticipants were found for age and gender (Age: participants; 47.03 SD [15.95],

nonparticipants; 46.37 SD [14.22], $P = 0.81$; Percentage male/female: participants; 21.4%/78.6%, nonparticipants; 23.9%/76.1%, $P = 0.87$), and for relevant clinical characteristics (participants vs participants: median pain at first presentation at the outpatient clinic [7.00 {interquartile range [IQR] 5.75–8.00} vs 6.00 {IQR 5.00–7.50}] $P = 0.29$; occurrence of allodynia: [50% vs 30%] $P = 0.69$; hyperesthesia [28% vs 30%] $P = 0.72$; hyperalgesia: [54% vs 37%] $P = 0.16$; hypoesthesia: [29% vs 32%] $P = 0.64$; hypoalgesia: [7% vs 11%] $P = 0.53$; edema: [100% vs 83%] $P = 0.42$; skin temperature differences: [86% vs 94%] $P = 0.15$).

Of 14 initially included patients, 3 patients did not finish the infusion week. One patient dropped out after 3 infusion days due to side effects (dizziness, headache and pain in infusion arm). Two patients dropped out after, respectively, 3 and 1 infusion days due to emotional reasons, not related to the intervention. One patient was excluded from the analysis due to a protocol violation.

In total, 10 patients (8 women and 2 men, mean age 44.00 SD [17.44]) completed the trial. Patient characteristics are shown in Table 1. All patients reported to have pain at baseline and all, except patient 1 and 2, experienced (reported and/or observed) additional signs and symptoms of central sensitization (Table 2). Prior to the intervention, patients used Paracetamol 500 mg (N = 2), Naproxen 220 mg (N = 1), Diclofenac 50 mg (N = 1), Brufen retard 800 mg (N = 1), or no pain medication (N = 7).




Figure 1 Flow of eligible subjects.

Effects on Sensory Disturbances

Figure 2 shows the median daily pain scores reported by patients. A significant reduction in pain week scores was found at all follow-up measurements compared with baseline (baseline values are presented in Table 2) for patients receiving magnesium (T1: $P = 0.01$, T3: $P = 0.04$, T6: 0.02, and T12: $P = 0.02$, respectively). At T12 the median box pain was 2.66 (IQR 0.37–5.50) (median pain reduction of 2.19 [IQR 1.62–2.52]). All patients showed a decrease of median week pain scores at T12 compared with baseline. A 50% decrease in pain intensity was observed at T12 in 4 patients (median pain decrease 72% [IQR 54.8–90.3%]), the remaining 4 patients had a median pain decrease of 20.6% (IQR 7.2–35.8%). The lowest and highest decrease in median box pain scores at T12 were, 0.58 (patient 6, pain decrease of 6.6%) and 6.52 points (patient 3; Figure 3, pain decrease of 100%). During the treatment, patient

Table 1 Patient characteristics, pain, and complaints of central sensitization at baseline

Mg	Patient Characteristics			Aspects of Central Sensitization at Baseline									
	Man/ Woman	Age (years)	Upper/Lower extremity	Duration CRPS (days)	Initial Trauma	Pain	Allodynia	Hyperesthesia	Hypoesthesia	Hyperalgesia	Hypoalgesia		
1	Man	59	Upper	61	Duptytren or.	Yes	No	No	No	No	No		
2	Woman	31	Lower	83	Sprain	Yes	No	No	No	No	No		
3	Woman	53	Upper	151	Fracture	Yes	Yes	No	No	No	No		
4	Woman	48	Upper	103	Fracture	Yes	Yes	Yes	Yes	No	No		
5	Woman	18	Lower	102	Fracture	Yes	No	No	Yes	No	No		
6	Man	30	Upper	64	Spontaneous	Yes	No	No	Yes	No	No		
7	Woman	62	Upper	123	Fracture	Yes	No	No	Yes	No	No		
8	Woman	65	Upper	176	Fracture	Yes	Yes	No	Yes	Yes	Yes		
9	Woman	21	Lower	82	Sprain	Yes	Yes	No	Yes	No	No		
10	Woman	53	Upper	112	Fracture	Yes	No	No	No	No	No		

Mg = magnesium; Pla = placebo.

Table 2 Baseline values of performed measures

	Baseline
Median week pain	6.67 (3.10–6.92)
Semmes Weinstein Monofilaments	0.15 (0.10–0.41)
ISS total	22.00 (17.25–25.75)
ISS box	7.50 (3.25–8.75)
ISS McGill	5.00 (3.00–5.00)
ISS temperature	1.50 (0.00–2.00)
ISS volume	3.00 (1.00–4.00)
ISS AROM	6.00 (4.25–7.75)
RSQ (N = 6)	3.05 (1.80–3.30)
WQ and QRSD (N = 2)	4.72 (4.63–4.80)
EuroQol	0.79 (0.53–0.80)
SF-36 Mental	74.00 (57.75–80.75)
Physical	50.50 (42.50–66.75)

ISS = Impairment Level Sumscore; AROM = active range of motion; RSQ = Radboud Skills Questionnaire; WQ and QRSD = Walking questionnaire and questionnaire rising and sitting down. Data in median (IQR).

6 experienced an inguinal hernia between measurement T6 and T12, which may have influenced the pain score measured at 12 weeks.

Data for the McGill Pain Questionnaire are shown in Table 3. A significant improvement was found for the McGill total number of words chosen (NWCt) at T1 compared with baseline (NWCt: median reduction: 2.00 [IQR 1.00–4.00], $P = 0.03$). In addition, a significant decline in NWC sensory and the value assigned to the chosen words (PRI) was found at T1 compared with baseline (NWCs: median reduction: 2.00 [IQR 2.00–3.00], $P = 0.03$ and PRIs: median reduction: 4.00 [IQR 3.00–6.00], $P = 0.03$). Furthermore, PRI evaluative improved significantly at T6 and T12 (median reduction of 1.00 [IQR 0.00–1.75], $P = 0.04$ and 1.50 [IQR 0.00–3.50], $P = 0.04$, respectively). No significant changes were found for PRI total, NWC evaluative and the affective subscale of the McGill Pain Questionnaire.

A reduction in absolute sensory thresholds differences as measured with the SWM was found at all follow up compared with baseline (baseline values are shown in Table 2) (median absolute sensory threshold reduction at T1: 0.06 [IQR –0.01–0.14], T2: 0.11 [IQR 0.04–0.16], T3: 0.07 [IQR –0.10–0.34], T6: 0.04 [IQR –0.01–0.37], T12: 0.05 [IQR 0.00–0.18]). However, these improvements were small and not statistically significant. None of the 10 patients reported allodynia during SWM testing.

Impairment Level Assessment

The ISS at baseline (baseline values are presented in Table 2) and differences scores at follow up are presented in Figure 4. ISS values were




Figure 2 Median pain scores per day at baseline, 1, 3, 6, and 12 weeks after magnesium treatment (N = 8). **P* < 0.05, Wilcoxon, follow up compared with baseline. Data in median (IQR).

predominantly moderate. A significant decrease of three points (IQR 1.00–7.00) was found at T12 compared with baseline (*P* = 0.03). Although this reduction was not clinically relevant for the group as a whole, 3 patients (patients 1, 3, and 5), showed clinical relevant improvement of 6.00, 8.00, and 7.00 points, respectively at T12 compared with baseline. Furthermore, a significant improvement was found for the ISS Box (pain during movement)

(Figure 5) at T1: improvement 1.00 (IQR 0.00–2.00), (*P* = 0.04), T3: improvement 2.00 (IQR 0.25–2.00), (*P* = 0.03), and T6: improvement 1.50 (IQR 1.00–2.00), (*P* = 0.02), and for the ISS AROM (Figure 6) at T6: improvement 1.25 (IQR 0.00–1.75), (*P* = 0.02) and T12: improvement 1.00 (IQR 1.00–1.00), (*P* = 0.01). No significant differences were found on other ISS parameters (temperature, volume, and McGill).




Figure 3 Median pain scores per week for patient 3 at baseline, 1, 3, 6, and 12 weeks after magnesium treatment.

Table 3 Baseline McGill Pain Questionnaire values and median changes at T1, T3, T6, and T12

	Baseline	Change at T1	Change at T3	Change at T6	Change at T12
NWCt	9.00 (6.00–9.75)	2.00 (1.00–4.00)*	1.00 (–2.00–4.75)	1.50 (–1.00–4.50)	3.00 (–1.00–6.00)
PRIt	12.50 (11.25–15.75)	4.00 (1.00–9.00)	2.00 (–2.50–9.00)	5.00 (–1.50–9.75)	7.50 (1.00–11.75)
NWCs	5.50 (3.25–6.00)	2.00 (2.00–3.00)*	2.00 (–1.00–3.00)	1.50 (–1.25–3.00)	2.50 (–0.50–4.75)
PRIs	8.00 (6.00–11.50)	4.00 (3.00–6.00)*	2.50 (–0.75–6.75)	4.00 (–2.50–7.00)	5.50 (0.00–9.75)
NWCe	2.50 (2.00–3.00)	0.00 (–1.00–1.00)	0.00 (–1.00–1.00)	0.00 (0.00–0.75)	0.00 (–1.00–1.00)
PRIe	4.00 (3.00–5.00)	0.00 (–1.00–1.00)	1.00 (–1.00–2.50)	1.00 (0.00–1.75)*	1.50 (0.00–3.50)*
NWCa	1.00 (0.25–1.00)	0.00 (0.00–0.00)	0.00 (–0.75–1.00)	0.00 (0.00–0.00)	0.00 (0.00–1.00)
PRIa	1.00 (0.25–1.75)	0.00 (–1.00–1.00)	0.00 (–0.75–0.75)	0.00 (–0.75–0.75)	0.50 (0.00–1.00)

* *P* < 0.05, Wilcoxon, follow-up compared with baseline.

NWC = number of words chosen; PRI = pain rating index; t = total; s = sensory subscale; e = evaluative subscale; a = affective subscale. Data in median (IQR).




Figure 4 ISS for patients at baseline, 1, 3, 6, and 12 weeks after magnesium treatment. ISS = Impairment Level SumScore. * $P < 0.05$, Wilcoxon, follow up compared with baseline. Data in median (IQR).

Activity Level Assessments

No significant change on activity level was found compared with baseline for the RSQ (T1: $P = 0.95$, T3: $P = 0.35$, T6: $P = 0.11$, T12: $P = 0.05$) and WQ and QRSD (T1: $P = 0.71$, T3: $P = 0.68$, T6: $P = 0.50$, T12: $P = 0.71$).

Quality of Life

Scores of the EuroQol and of the physical health domain of the SF-36 improved significantly at 12 weeks compared with baseline (EuroQol improvement: 0.06 [IQR 0.00–0.32]), $P = 0.04$ and SF-36 physical health improvement 9.50 [IQR 7.25–




Figure 5 ISS Box pain during movement for patients at baseline, 1, 3, 6, and 12 weeks after magnesium treatment. ISS = Impairment Level SumScore. * $P < 0.05$, Wilcoxon, follow up compared with baseline. Data in median (IQR).




Figure 6 ISS AROM for patients at baseline, 1, 3, 6, and 12 weeks after magnesium treatment. ISS = Impairment Level SumScore; AROM = active range of motion. * $P < 0.05$, Wilcoxon, follow up compared with baseline. Data in median (IQR).

22.50], $P = 0.01$). Patients 3, 4, and 6 in particular showed improvement on the EuroQol (improvement 0.27, 0.34, and 0.47). An improvement on the physical domain of the SF-36 was seen in patients 3, 5 and 6 (improvement of 37.00, 21.00, 23.00 points, respectively).

Tolerability and Safety Measurements

Patients receiving both interventions (placebo and magnesium) experienced mild side effects. Side effects for the magnesium group were infusion site pain ($N = 5$), flushing ($N = 4$), nausea ($N = 2$), vomiting ($N = 1$), fatigue ($N = 4$), headache ($N = 1$), dry mouth ($N = 1$), burning eyes ($N = 4$), palpitations ($N = 1$), dizziness ($N = 4$), lightheadedness ($N = 2$), and diarrhea ($N = 1$). The 2 patients receiving placebo both experienced nausea and fatigue. All cannula were placed in the unaffected hand. In 5 patients, the intravenous cannulation had to be replaced due to sensitivity at the infusion site. After replacement, the cannula remained *in situ* uneventfully.

Four out of 8 patients receiving magnesium had elevated magnesium plasma levels at the first day after the start of the intervention (mean magnesium level of 1.25 [SD 0.23]), which normalized during the following days of the infusion. The remaining 4 patients exhibited normal magnesium plasma levels (between 0.70 and 1.00 mmol/L) during the course of the magnesium infusion. No serious adverse events were reported.

Success of Blinding

Success of blinding was determined by asking patients and researcher which treatment they thought the patient had received. All patients thought to have received the magnesium treatment, including both patients receiving placebo. The researcher was not able to single out the 2 patients receiving the placebo infusion.

Discussion

The results of this pilot study show significant benefits of intravenous magnesium treatment on complaints and quality of life in CRPS 1 patients. Pain reported by patients was significantly decreased. Moreover, sensory disturbances as measured with the McGill NWcT, NWcS, and PRI were significantly improved at 1 week after magnesium treatment.

These results are in line with results of other studies with regard to the efficacy of magnesium

on neuropathic pain, whereby pain scores were significantly lower after magnesium infusion administration compared with placebo in patients with postherpetic neuralgia [20] and after a single dose of intravenous magnesium, partial to complete pain relief was found in cancer patients with neuropathic pain up to 4 hours [22]. In these studies, however, the reduction in pain was observed quite instant (at 20 and 30 minutes), which may be related to the higher levels of magnesium administered in a shorter period of time than was the case in our study. We investigated the effect of magnesium administration for a substantially longer period, and found the pain rating to be significantly reduced up to 12 weeks.

These promising results may be indicative for the role of central sensitization in the development of (sensory) complaints. By blocking the NMDA receptor calcium channel, and preventing the influx of calcium and the initiation of an intracellular cascade, magnesium may impede peripheral and/or central sensitization resulting in a reduction of pain [36]. Possibly, also other aspects of sensitization often displayed in CRPS 1, such as allodynia and hyperalgesia may be abolished after magnesium treatment. In the present study, only pain was evaluated at follow up, therefore, no information can be presented at this point about the effect of magnesium on other aspects of peripheral or central sensitization.

An unexpected result of this study is the low baseline pain scores of some of our patients. Patients were recruited at our outpatient clinic during consulting hours and were only included in our study if they had a VAS pain score of 5 or higher. After inclusion into our trial, 3 patients had lower baseline median pain scores. Patients expectancies, disease progress, and regression to the mean may have contributed to this drop in pain at baseline.

In addition to pain, patients also showed significant improvement on impairment as measured with the ISS. This improvement was, in contrast to the reduction of pain, only found at 12 weeks. Possibly, changes in indices measured with the ISS other than pain are modulated in a more gradual manner by the magnesium treatment. Furthermore, patients who participated in our study had relatively low baseline ISS scores compared with ISS scores of CRPS 1 patients in other studies [8,25]. Possibly, the ISS was not able to decrease a lot due to already low ISS scores.

Besides the treatment with magnesium, all patients also received physical therapy according to a fixed treatment protocol [8,25]. Although physical therapy was shown to have a positive effect on pain [37], we believe that the observed reduction in pain may be related to the administration of magnesium. In our study, the standardized physical therapy was started 1 week prior to baseline, and continued for the duration of the trial. Furthermore, the reduction of pain intensity was only observed after the start of the infusion week and not during the baseline week. However, we cannot exclude some beneficial effect of physical therapy at this point, and the applied physical therapy may have contributed to the improvement in impairment seen at 12 weeks.

This pilot study revealed only limited side effects following magnesium infusion. Four out of 8 patients receiving magnesium had normal plasma levels (between 0.70 and 1.0 mmol/L) the day following the infusion. The elevated magnesium plasma levels found in the other 4 patients receiving placebo might be explained by higher body mass index (BMI) indexes (mean BMI = 34.28 [SD 3.98] vs 26.26 [SD 5.30]), resulting in higher doses of magnesium. Furthermore, intravenous magnesium is used in a broad range of indications (e.g., pre-eclampsia and eclampsia) and was shown to be safe and tolerable in studies using higher dosages than we have used in the present study [38,39].

One could argue, however, that the positive results found in this study could be attributed to the high probability of finding significant differences using the current design with multiple testing [40]. Although the probability of chance findings cannot be ruled out at this point, the high number of significant results found in this pilot study, which are in line with prior theoretical considerations with respect to the expected mode of action of magnesium in relation to the mechanism of sensitization presumed in CRPS 1 [15], would make this less likely in our opinion. Furthermore, the current research design makes it difficult to exclude the role of natural disease recovery and regression to the mean for these patients with a relatively short disease duration. In a future study, the effects of magnesium should be evaluated for patients less prone to natural change in disease severity (i.e., patients with chronic CRPS 1). In addition, sensory disturbances associated with central sensitization may be even more prominent in chronic CRPS 1 patients [41], making inclusion of this subgroup of patients even more relevant.

Consequently, we have started a Randomized Controlled Trial in which in a parallel design the effects of intravenous magnesium sulphate on pain, other aspects of central sensitization and impairment in a group of acute and chronic CRPS 1 patients is investigated.

Conclusion

The significant improvement of pain, impairment, and quality of life after the treatment with intravenous magnesium suggest that magnesium has beneficial effects on CRPS 1 complaints. Intravenous magnesium was well tolerated and resulted in mild side effects. These results are encouraging and suggest that the potential of IV magnesium as a treatment in CRPS 1 should be further explored in a large size formal trial design.

Acknowledgments

This study is part of TREND (Trauma RElated Neuronal Dysfunction), a knowledge consortium that integrates research on CRPS 1. This project is supported by a Dutch Government grant (BSIK03016).

References

- 1 Marinus J, Van Hilten JJ. Clinical expression profiles of complex regional pain syndrome, fibromyalgia and a-specific repetitive strain injury: More common denominators than pain? *Disabil Rehabil* 2006;28:351–62.
- 2 Perez RSGM, Collins S, Marinus J, Zuurmond WWA, de Lange JJ. Diagnostic criteria for CRPS I: Differences between patient profiles using three different diagnostic sets. *European Journal of Pain* 2007;11:895–902.
- 3 Veldman PHJM, Reynen HM, Arntz IE, et al. Signs and symptoms of reflex sympathetic dystrophy—Prospective-Study of 829 patients. *Lancet* 1993; 342:1012–6.
- 4 Huygen FJPM, de Bruijn AGJ, de Bruin MT, et al. Evidence for local inflammation in complex regional pain syndrome type 1. *Mediators Inflamm* 2002;11: 47–51.
- 5 Weber M, Birklein F, Neundorfer B, et al. Facilitated neurogenic inflammation in complex regional pain syndrome. *Pain* 2001;91:251–7.
- 6 Oyen WJG, Arntz IE, Claessens RAMJ, et al. Reflex sympathetic dystrophy of the hand: An excessive inflammatory response? *Pain* 1993;55:151–7.
- 7 van der Laan L, Goris RJA. Reflex sympathetic dystrophy—An exaggerated regional inflammatory response? *Hand Clin* 1997;13:373.

- 8 Perez RSGM, Zuurmond WWA, Bezemer PD, et al. The treatment of complex regional pain syndrome type I with free radical scavengers: A randomized controlled study. *Pain* 2003;102:297–307.
- 9 Zuurmond WWA, Langendijk PNJ, Bezemer PD, et al. Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. *Acta Anaesthesiol Scand* 1996;40:364–7.
- 10 Lee CJ, Bardoni R, Tong CK, et al. Functional expression of AMPA receptors on central terminals of rat dorsal root ganglion neurons and presynaptic inhibition of glutamate release. *Neuron* 2002;35:135–46.
- 11 Bennett GJ. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-receptor. *J Pain Symptom Manage* 2000;19:S2–6.
- 12 Petrenko AB, Yamakura T, Baba H, et al. The Role of N-Methyl-D-Aspartate (NMDA) receptors in pain: A review. *Anesth Analg* 2003;97:1108–16.
- 13 Carlton SM, Coggeshall RE. Inflammation-induced changes in peripheral glutamate receptor populations. *Brain Res* 1999;820:63–70.
- 14 Farajidavar A, Gharibzadeh S, Towhidkhan F, et al. A cybernetic view on wind-up. *Med Hypotheses* 2006;67:304–6.
- 15 Schwartzman RJ, Alexander GM, Grothusen J. Pathophysiology of complex regional pain syndrome. *Expert Rev Neurother* 2006;6:669–81.
- 16 Liu HT, Hollmann MW, Liu WH, et al. Modulation of NMDA receptor function by ketamine and magnesium: Part I. *Anesth Analg* 2001;92:1173–81.
- 17 Levaux C, Bonhomme V, Dewandre PY, et al. Effect of intra-operative magnesium sulphate on pain relief and patient comfort after major lumbar orthopaedic surgery. *Anaesthesia* 2003;58:131–5.
- 18 Tramer MR, Schneider J, Marti RA, et al. Role of magnesium sulfate in postoperative analgesia. *Anesthesiology* 1996;84:340–7.
- 19 Mikkelsen S, Dirks J, Fabricius P, et al. Effect of intravenous magnesium on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. *Br J Anaesth* 2001;86:871–3.
- 20 Brill S, Sedgwick PM, Hamann W, et al. Efficacy of intravenous magnesium in neuropathic pain. *Br J Anaesth* 2002;89:711–4.
- 21 Tanaka M, Shimizu S, Nishimura W, et al. Relief of neuropathic pain with intravenous magnesium. *Masui* 1998;47:1109–13.
- 22 Crosby V, Wilcock A, Corcoran R. The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. *J Pain Symptom Manage* 2000;19:35–9.
- 23 Stanton-Hicks M, Janig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: Changing concepts and taxonomy. *Pain* 1995;63:127–33.
- 24 World Health Organization. WHO Guidelines: Cancer Pain Relief. Geneva: World Health Organization; 1996.
- 25 Oerlemans HM, Oostendorp RAB, de Boo T, et al. Adjuvant physical therapy versus occupational therapy in patients with reflex sympathetic dystrophy/complex regional pain syndrome type I. *Arch Phys Med Rehabil* 2000;81:49–56.
- 26 van der Kloot WA, Oostendorp RA, van der MJ, et al. [The Dutch version of the McGill pain questionnaire: A reliable pain questionnaire]. *Ned Tijdschr Geneesk* 1995;139:669–73.
- 27 Rommel O, Malin JP, Zenz M, et al. Quantitative sensory testing, neurophysiological and psychological examination in patients with complex regional pain syndrome and hemisensory deficits. *Pain* 2001;93:279–93.
- 28 Oerlemans HM, Goris RJA, Oostendorp RAB. Impairment level sumscore in reflex sympathetic dystrophy of one upper extremity. *Arch Phys Med Rehabil* 1998;79:979–90.
- 29 Perez RSGM, Oerlemans HM, Zuurmond WWA, et al. Impairment level SumScore for lower extremity Complex Regional Pain syndrome type I. *Disabil Rehabil* 2003;25:984–91.
- 30 Oerlemans HM, Perez RSGM, Oostendorp RAB, et al. Objective and subjective assessments of temperature differences between the hands in reflex sympathetic dystrophy. *Clin Rehabil* 1999;13:430–8.
- 31 Oerlemans HM, Cup EHC, de Boo T, et al. The Radboud skills questionnaire: Construction and reliability in patients with reflex sympathetic dystrophy of one upper extremity. *Disabil Rehabil* 2000;22:233–45.
- 32 Roorda LD, Roebroek ME, van Tilburg T, et al. Measuring activity limitations in walking: Development of a hierarchical scale for patients with lower-extremity disorders who live at home. *Arch Phys Med Rehabil* 2005;86:2277–83.
- 33 Kemler MA, De Vet HCW. Health-related quality of life in chronic refractory reflex sympathetic dystrophy (complex regional pain syndrome type I). *J Pain Symptom Manage* 2000;20:68–76.
- 34 EuroQol—A new facility for the measurement of health-related quality of life. The EuroQol Group. *Health Policy* 1990;16:199–208.
- 35 Fontaine N, Rosengren B. Directive 2001/20/EC of the European parliament and the council. *Official Journal of the European Communities* 2001;L121/34–L121/44.
- 36 Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. *Pain* 1991;44:293–9.

- 37 Oerlemans HR, Oostendorp RAB, de Boo T, et al. Pain and reduced mobility in complex regional pain syndrome I: Outcome of a prospective randomised controlled clinical trial of adjuvant physical therapy versus occupational therapy. *Pain* 1999;83:77–83.
- 38 Haghghi L. Prevention of preterm delivery: Nifedipine or magnesium sulfate. *Int J Gynecol Obstet* 1999;66:297–8.
- 39 Zygmunt M, Heilmann L, Berg C, et al. Local and systemic tolerability of magnesium sulphate for tocolysis. *Eur J Obstet Gynecol Reprod Biol* 2003; 107:168–75.
- 40 Altman DG. *Practical Statistics for Medical Research*. London: Chapman and Hall; 1991.
- 41 Birklein F, Riedl B, Sieweke N, et al. Neurological findings in complex regional pain syndromes—Analysis of 145 cases. *Acta Neurol Scand* 2000; 101:262–9.

Copyright of *Pain Medicine* is the property of Blackwell Publishing Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.